133 related articles for article (PubMed ID: 9667246)
1. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson LE; O'Brien S
J Clin Oncol; 1998 Jul; 16(7):2321-31. PubMed ID: 9667246
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
5. Deoxyribonucleoside triphosphate pools in regenerating rat liver: effect of hydroxyurea and exogenous deoxypyrimidines.
Röttgen V; Rabes HM
Biochim Biophys Acta; 1989 Sep; 992(3):349-54. PubMed ID: 2775790
[TBL] [Abstract][Full Text] [Related]
6. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Giles FJ; Fracasso PM; Kantarjian HM; Cortes JE; Brown RA; Verstovsek S; Alvarado Y; Thomas DA; Faderl S; Garcia-Manero G; Wright LP; Samson T; Cahill A; Lambert P; Plunkett W; Sznol M; DiPersio JF; Gandhi V
Leuk Res; 2003 Dec; 27(12):1077-83. PubMed ID: 12921943
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of high-dose continuous-infusion hydroxyurea.
Smith DC; Vaughan WP; Gwilt PR; Trump DL
Cancer Chemother Pharmacol; 1993; 33(2):139-43. PubMed ID: 8261572
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
11. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Newman EM; Carroll M; Akman SA; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Shibata S; Somlo G; Tetef M; Yen Y; Ahn CW; Doroshow JH
Cancer Chemother Pharmacol; 1997; 39(3):254-8. PubMed ID: 8996529
[TBL] [Abstract][Full Text] [Related]
13. Quantification of hydroxyurea in human plasma by HPLC-MS/MS and its application to pharmacokinetics in patients with chronic myeloid leukaemia.
Hai X; Guo M; Gao C; Zhou J
J Pharm Biomed Anal; 2017 Apr; 137():213-219. PubMed ID: 28131939
[TBL] [Abstract][Full Text] [Related]
14. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.
Garcia AA; Muggia FM; Spears CP; Jeffers S; Silberman H; Pujari M; Koda RT
Anticancer Drugs; 2001 Jul; 12(6):505-11. PubMed ID: 11459996
[TBL] [Abstract][Full Text] [Related]
16. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
Bakshi RP; Hamzeh F; Frank I; Eron JJ; Bosch RJ; Rosenkranz SL; Cramer YS; Ussery M; Flexner C
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1360-5. PubMed ID: 18184078
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models.
Tosi P; Visani G; Ottaviani E; Tura S; Darnowski JW
Eur J Haematol; 1994 May; 52(5):291-5. PubMed ID: 8020629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
